Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15123
UPID:
ANGP2_HUMAN
Alternative names:
-
Alternative UPACC:
O15123; A0AV38; A8K205; B7ZLM7; Q9NRR7; Q9P2Y7
Background:
Angiopoietin-2, a key regulator of angiogenesis, binds to the TEK/TIE2 receptor, modulating its signaling pathways. It competes with ANGPT1 for binding sites, influencing vascular development and remodeling. Angiopoietin-2's role extends to endothelial cell apoptosis and vascular regression in the absence of angiogenic inducers, while in their presence, it promotes endothelial cell migration and proliferation.
Therapeutic significance:
Angiopoietin-2's involvement in lymphatic malformation 10, a form of primary lymphedema, underscores its therapeutic potential. Targeting Angiopoietin-2 could lead to innovative treatments for lymphedema, offering hope for patients suffering from this debilitating condition.